Vitamin B5 Synergistic 250 mg
Natural health product licensed in Canada
If this product were sold in France
- Dose déclarée au-delà d'une limite
Vitamine C: up to 200 mg a day according to the dosing instructions published by Health Canada (1 unités posologiques par jour au plus, pour les adultes), above the maximum dose of 180 mg set in France for a food supplement (2006 Order, not revised since November 2006).
arrêté du 9 mai 2006, annexe III. French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
- À vérifier
Serratiopeptidase is listed in the Novel Food Catalogue as a novel food not yet authorised in the European Union: in the form covered by the entry, it should not be sold until authorised. The catalogue is informative; a declaration in France is not an authorisation.
POL-NF-00692. Novel Food Catalogue (status of products under Regulation (EU) 2015/2283), retrieved 21 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Serratiopeptidase Source : Serratia marcescens (E-15) Potency : 0.498666667 FCC SU | 0.000187 mg | Not calculated |
| alpha-L-arabinofuranoside arabinofuranohydrolase Source : Aspergillus niger - En entier Potency : 0.0888 FCC HCU | 0.000225 mg | Not calculated |
| Protéase fongique Source : Aspergillus niger - En entier Potency : 0.152 FCC SAPU | 0.07484 mg | Not calculated |
| bêta-fructofuranosidase Source : Saccharomyces spp. Potency : 0.213325 FCC INVU | 0.00325 mg | Not calculated |
| myo-Inositol-hexakisphosphate 3-phosphohydrolase Source : Aspergillus niger - En entier Potency : 0.006675 FCC FTU | 0.003325 mg | Not calculated |
| Arthrospira platensis Source : En entier | 10 mg | Not calculated |
| Arthrospira platensis Source : Arthrospira platensis | 10 mg | Not calculated |
| Gelée royale Source : Apis mellifera - sécrétion Potency : 6 % 10-hydroxy-2-decenoic acid | 10 mg | Not calculated |
| Astragalus membranaceus Source : Astragalus membranaceus - racine Extraction ratio : 6:1 Dry plant equivalent : 12 mg Potency : 16 % Polysaccharides | 2 mg | Not calculated |
| Poly(1-4-a-D-galacturonide)glycanohydrolase Source : Aspergillus niger - En entier Potency : 0.16 Endo-PGU | 0.0016 mg | Not calculated |
| Protéase fongique Source : Aspergillus niger - En entier Potency : 110.4975 FCC HUT | 0.39916 mg | Not calculated |
| Acide pantothénique Source : d-panthothénate de calcium | 250 mg | 250,000 µg |
| Vitamine C Source : Acide ascorbique | 200 mg | 200,000 µg |
| Vitamine C Source : Vitamine C | 200 mg | 200,000 µg |
| alpha-D-Galactoside galactohydrolase Source : Aspergillus niger - En entier Potency : 0.050675 FCC AGU | 0.003375 mg | Not calculated |
| 4-alpha-D-glucane glucanohydrolase Source : Aspergillus flavus var. oryzae - En entier Potency : 31.4975 Unités d'alpha-amylase dextrinifiante du FCC | 0.252 mg | Not calculated |
| Bromélaïne de tige Source : Tige(s) Potency : 1,920 FCC PU | 0.053325 mg | Not calculated |
| 4-(1,3;1,4)-bêta-D-glucane 4-glucanohydrolase Source : Aspergillus niger - En entier Potency : 3.36 FCC CU | 0.028 mg | Not calculated |
| 1,4-alpha-D-Glucane glucohydrolase Source : Aspergillus niger - En entier Potency : 0.133325 FCC AGU | 0.111125 mg | Not calculated |
| bêta-D-galactoside galactohydrolase Source : Aspergillus flavus var. oryzae - En entier Potency : 11.450675 FCC ALU | 0.0145 mg | Not calculated |
| Triacylglycérol acylhydrolase Source : Aspergillus niger - En entier Potency : 5.3325 FCC LU | 0.02 mg | Not calculated |
| Diastase du malt Source : Aspergillus niger - En entier Potency : 0.3475 FCC DP | 0.008675 mg | Not calculated |
| papaïne Source : Carica papaya, fruit Potency : 800 FCC PU | 0.008 mg | Not calculated |
| Protéase bactérien Source : Bacillus subtilis Potency : 12 FCC PC | 0.02495 mg | Not calculated |
| Protéase bactérien Source : En entier Potency : 12 FCC PC | 0.02495 mg | Not calculated |
Non-medicinal ingredients
Eau purifiée, Stéarate de magnésium, Hypromellose, Dioxyde de silicium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 1 Capsule | 1 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Multi-vitamin supplement. Vitamin B5 is a factor in the maintenance of good health; helps the body to metabolize carbohydrates, fats and proteins; helps in tissue formation. Vitamin B5 supplementation helps to prevent Vitamin B5 deficiency. Vitamin C is a factor in the maintenance of good health; an antioxidant for the maintenance of good health; helps the body to metabolize fats and proteins; helps in the maintenance of bones, cartilage, teeth and gums; helps in wound healing. Vitamin C supplementation helps to prevent Vitamin C deficiency.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Product record
- Licence holder
- Vitazan Herbs and Vitamins Inc
- NPN or DIN-HM
- 80053792
- Status
- Active licence
- Licence date
- 11 September 2014
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
Source
Official Health Canada record, licence 80053792
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Serratiopeptidase
Read the warning, when it applies and the studies cited
SERRAPEPTASE
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have gastrointestinal lesions/ulcers, a kidney or liver disorder, or are having surgery (Bhagat et al. 2013; Chopra et al. 2009; Al- Khateeb and Nusair 2008; Mazzone et al. 1990).
Sources cited by Health Canada (4)
- Bhagat S, Agarwal M and Roy V. Serratiopeptidase : A systemic review of the existing evidence. International Journal of Surgery 2013;11(3):209-217 PubMed Systematic review
- Chopra D, Rehan HS, Mehra P, et al. A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of paracetamol, serratiopeptidase, ibuprofen and betamethasone using the dental impaction pain model. International Journal of Oral Maxillofacial Surgery 2009;38:350-355. PubMed Randomised trial
- Mazzone A, Catalani M, Costanzo M, et al. Evaluation of serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology : a multicentre, double-blind, randomized trial versus placebo. Journal of International Medical Research 1990;18:379-388. PubMed Randomised trial
- Al-Khateeb TH and Nusair Y. Effect of the proteolytic enzyme serrapeptase on swelling, pain and trismus after surgical extraction of mandibular third molars. International Journal of Oral Maxillofacial Surgery 2008;37:264-268. PubMed Randomised trial
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners or anti-inflammatory medications (Bhagat et al. 2013; Chopra et al. 2009; Al-Khateeb and Nusair 2008; Mazzone et al. 1990).
Sources cited by Health Canada (4)
- Al-Khateeb TH and Nusair Y. Effect of the proteolytic enzyme serrapeptase on swelling, pain and trismus after surgical extraction of mandibular third molars. International Journal of Oral Maxillofacial Surgery 2008;37:264-268. PubMed Randomised trial
- Bhagat S, Agarwal M and Roy V. Serratiopeptidase : A systemic review of the existing evidence. International Journal of Surgery 2013;11(3):209-217 PubMed Systematic review
- Chopra D, Rehan HS, Mehra P, et al. A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of paracetamol, serratiopeptidase, ibuprofen and betamethasone using the dental impaction pain model. International Journal of Oral Maxillofacial Surgery 2009;38:350-355. PubMed Randomised trial
- Mazzone A, Catalani M, Costanzo M, et al. Evaluation of serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology : a multicentre, double-blind, randomized trial versus placebo. Journal of International Medical Research 1990;18:379-388. PubMed Randomised trial
Known adverse reactions
Stop use if rash, difficulty breathing, hypersensitivity and/or severe allergy occur (Bhagat et al. 2013; Balagi 2007).
Sources cited by Health Canada (1)
- Bhagat S, Agarwal M and Roy V. Serratiopeptidase : A systemic review of the existing evidence. International Journal of Surgery 2013;11(3):209-217 PubMed Systematic review
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
- Gelée royale
Read the warning, when it applies and the studies cited
ROYAL JELLY
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Contraindications
Do not use if you have a history of asthma or allergies (TGA 2001; Leung et al. 1997; Harwood et al. 1996; Laporte et al. 1996; Thien et al. 1996; Leung et al. 1995; Peacock et al. 1995; Bullock 1994).
Sources cited by Health Canada (8)
- Bullock RJ. Fatal royal-jelly induced asthma. Medical Journal of Australia 1994;160:44. PubMed Case report
- Harwood M, Harding S, Beasley R, Frankish PD. Asthma following royal jelly. The New Zealand Medical Journal 1996;109:325. PubMed Case report
- Laporte JR, Ibaanez L, Vendrell L, Ballarin E. Bronchospasm induced by royal jelly. Allergy 1996;51:440. PubMed
- Leung R, Ho A, Chan J, Choy D, Lai CK. Royal jelly consumption and hypersensitivity in the community. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1997;27(3):333-336. PubMed
- Leung R, Thien FC, Baldo B. Royal Jelly-induced asthma and anaphylaxis: clinical characteristics and immunologic correlations. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1995;96:1004-1007. PubMed Case report
- Peacock S, Muray V, Turton C. Respiratory distress and royal jelly. British Medical Journal 1995;311:1472. PubMed Case report
- TGA 2001: Australian Therapeutic Goods Administration. CMEC 28: Complementary Medicines Evaluation Committee, Extracted Ratified Minutes twenty-eight Meeting, 27-28 July 2001. Australian Government Department of Health and Aging, Sydney, Australia; 2001. [Accessed 2025 February 5]. Available from: https://www.tga.gov.au/sites/default/files/cmec-minutes-28.pdf
- Thien FC, Leung R, Baldo BA, Weiner JA, Plomley R, Czarny D. Asthma and anaphylaxis induced by royal jelly. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1996;26(2):216-222. PubMed
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (Leung et al. 1997; Laporte et al. 1996; Thien et al. 1996; Leung et al. 1995; Peacock et al. 1995).
Sources cited by Health Canada (6)
- Laporte JR, Ibaanez L, Vendrell L, Ballarin E. Bronchospasm induced by royal jelly. Allergy 1996;51:440. PubMed
- Leung R, Ho A, Chan J, Choy D, Lai CK. Royal jelly consumption and hypersensitivity in the community. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1997;27(3):333-336. PubMed
- Leung R, Thien FC, Baldo B. Royal Jelly-induced asthma and anaphylaxis: clinical characteristics and immunologic correlations. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1995;96:1004-1007. PubMed Case report
- Peacock S, Muray V, Turton C. Respiratory distress and royal jelly. British Medical Journal 1995;311:1472. PubMed Case report
- Thien FC, Leung R, Baldo BA, Weiner JA, Plomley R, Czarny D. Asthma and anaphylaxis induced by royal jelly. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1996;26(2):216-222. PubMed
- Harwood M, Harding S, Beasley R, Frankish PD. Asthma following royal jelly. The New Zealand Medical Journal 1996;109:325. PubMed Case report
- Astragalus membranaceus
Read the warning, when it applies and the studies cited
ASTRAGALUS - ASTRAGALUS MEMBRANACEUS
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have an autoimmune disorder (Brinker 2010; Upton 1999).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Upton R, editor. American Herbal Pharmacopoeia and Therapeutic Compendium: Astragalus Root. Santa Cruz (CA): American Herbal Pharmacopoeia; 1999.
Contraindications
Condition of application: Traditional Chinese Medicine.
Do not use if you have exterior excess, stagnation, yin deficiency or excess heat (Bensky et al. 2004; Chen and Chen 2004).
Sources cited by Health Canada (2)
- Bensky D, Clavey, Stöger E, Gamble A. Chinese Herbal Medicine: Materia Medica. 3rd edition. Seattle (WA): Eastland Press, Incorporated; 2004.
- Chen JK, Chen TT. Chinese Medical Herbology and Pharmacology. Crampton L, editor. City of Industry (CA): Art of Medicine Press Inc.; 2004.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Vitamin B5 Synergistic 250 mg (Vitazan Herbs and Vitamins Inc): composition and ingredients”, https://compoatlas.com/en/supplements/canada/80053792-vitamin-b5-synergistic-250-mg, updated 11 September 2014.